Mr William David Wiley, RPH in Glasgow, KS - Pharmacist

Mr William David Wiley, RPH is a Pharmacist based in Glasgow, Kansas. Mr William David Wiley is licensed to practice in Kentucky (license number 008425) and his current practice location is 1001 West Main St., Glasgow, Kansas. He can be reached at his office (for appointments etc.) via phone at (270) 651-0471.

NPI number for Mr William David Wiley is 1518240522 and his current mailing address is 1001 West Main St., Glasgow, Kansas. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1518240522.

Contact Information

	Mr William David Wiley, RPH
	1001 West Main St., Glasgow, KS 42141
	(270) 651-0471
	(270) 659-0147

Healthcare Provider's Profile

Full Name	Mr William David Wiley
Gender	Male
Speciality	Pharmacist
Location	1001 West Main St., Glasgow, Kansas
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1518240522
Provider Enumeration Date: 09/26/2011
Last Update Date: 09/26/2011

Medical Identifiers

Medical identifiers for Mr William David Wiley such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1518240522	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
183500000X	Pharmacist	008425 (Kentucky)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Mr William David Wiley is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Mr William David Wiley, RPH 1001 West Main St., Glasgow, KS 42141 Ph: (270) 651-0471	Mr William David Wiley, RPH 1001 West Main St., Glasgow, KS 42141 Ph: (270) 651-0471

News Archive

Restrictions by health insurers and government to control expenses may hurt the malignant melanoma drug market

Decision Resources, Inc., a research and advisory firms focusing on pharmaceutical and health care issues, finds that restrictions by health insurers and government health authorities to control expenses may hurt the malignant melanoma drug market.

Almac launches six enzyme screening kits

As anticipated, Almac's biocatalysis business has expanded from its 2009 launch with the sale of six enzyme screening kits, to the current supply of 100s of kgs of chiral intermediates for drug substance manufacture, regular enzyme supply to specialty chemical companies and continued growth of its screening kits offering. Biocatalysis is increasingly recognised as an alternative solution for solving complex chemistry problems due to its rapid implementation, economic benefits and 'green' reputation.

Sleep medicine and research: an interview with James K. Walsh

There are a variety of sleep medicines. I am going to refer to what are commonly described as hypnotics or sleeping pills. Sleeping pills have been around for a long time.

MPI Research to assist Kineta in autoimmune drug development program

MPI Research, a preclinical Contract Research Organization (CRO), announced that it will be collaborating with Kineta, Inc, a Seattle-based privately held biotechnology company specializing in clinical advancement of drugs that modulate and enhance the human immune system.

Mr William David Wiley, RPH - Pharmacist in Glasgow, KS